Cardiotoxicities of Non-Chemotherapeutic Metastatic Breast Cancer Treatments

被引:0
作者
Soltani, Marwa [1 ,2 ]
Sokoloff, Lara J. [1 ,3 ]
Fradley, Michael G. [1 ,2 ]
机构
[1] Univ Penn, Div Cardiol, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Perelman Ctr Adv Med, East Pavil 2nd Floor,3400 Civ Ctr Blvd, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Med, Hosp, 3400 Spruce St,100 Centrex, Philadelphia, PA 19104 USA
关键词
Metastatic breast cancer; Human epidermal growth factor 2-positive; Hormone receptor-positive; Triple negative disease; Targeted therapies; Cardiotoxicity; Cardio-oncology; GLOBAL LONGITUDINAL STRAIN; DOUBLE-BLIND; HERCEPTIN ADJUVANT; AMERICAN SOCIETY; CARDIAC EVENTS; TRASTUZUMAB; THERAPY; PHASE; WOMEN; PERTUZUMAB;
D O I
10.1007/s11912-023-01427-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of ReviewAlthough mortality rates have declined significantly in recent years, breast cancer remains the second most common cause of cancer death in women, with rates significantly higher among women with metastatic disease. New therapeutic agents have improved the prognosis of patients with metastatic breast cancer but raise concerns around the risk of cardiovascular disease. This review aims to discuss the oncologic treatment of the different subtypes of breast cancer along with the cardiac complications associated with each therapy.Recent FindingsThis article emphasizes human epidermal growth factor receptor targeted therapies with a focus on incidence of cardiotoxicity, reversibility, long-term outcomes, and management in high-risk patients. This review will address the use of cardiac biomarkers to monitor for toxicity, as well as the utility of cardiac imaging, including global longitudinal strain as a prognostic factor. We will also include recent findings on tyrosine kinase inhibitors, cyclin dependent kinase 4/6, and immune checkpoint inhibitors.Cardiotoxicity may lead to premature discontinuation of novel cancer therapies; optimizing cardiovascular risk factors and close monitoring for cardiotoxicity allow patients to maximize their oncologic and cardiovascular outcomes.
引用
收藏
页码:923 / 935
页数:13
相关论文
共 77 条
[31]   Aromatase Inhibitors and the Risk of Cardiovascular Outcomes in Women With Breast Cancer A Population-Based Cohort Study [J].
Khosrow-Khavar, Farzin ;
Filion, Kristian B. ;
Bouganim, Nathaniel ;
Suissa, Samy ;
Azoulay, Laurent .
CIRCULATION, 2020, 141 (07) :549-559
[32]   Long-term follow-up assessment of cardiac safety in SAFE-HEaRt, a clinical trial evaluating the use of HER2-targeted therapies in patients with breast cancer and compromised heart function [J].
Khoury, Katia ;
Lynce, Filipa ;
Barac, Ana ;
Geng, Xue ;
Dang, Chau ;
Yu, Anthony F. ;
Smith, Karen L. ;
Gallagher, Christopher ;
Pohlmann, Paula R. ;
Nunes, Raquel ;
Herbolsheimer, Pia ;
Warren, Robert ;
Srichai, Monvadi B. ;
Hofmeyer, Mark ;
Asch, Federico ;
Tan, Ming ;
Isaacs, Claudine ;
Swain, Sandra M. .
BREAST CANCER RESEARCH AND TREATMENT, 2021, 185 (03) :863-868
[33]   Olaparib protects cardiomyocytes against oxidative stress and improves graft contractility during the early phase after heart transplantation in rats [J].
Korkmaz-Icoez, Sevil ;
Szczesny, Bartosz ;
Marcatti, Michela ;
Li, Shiliang ;
Ruppert, Mihaly ;
Lasitschka, Felix ;
Loganathan, Sivakkanan ;
Szabo, Csaba ;
Szabo, Gabor .
BRITISH JOURNAL OF PHARMACOLOGY, 2018, 175 (02) :246-261
[34]   Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity [J].
Lambert, James ;
Lamacie, Mariana ;
Thampinathan, Babitha ;
Altaha, Mustafa A. ;
Esmaeilzadeh, Maryam ;
Nolan, Mark ;
Fresno, Camila Urzua ;
Somerset, Emily ;
Amir, Eitan ;
Marwick, Thomas H. ;
Wintersperger, Bernd J. ;
Thavendiranathan, Paaladinesh .
HEART, 2020, 106 (11) :817-823
[35]   Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity A Phase I Trial [J].
Leong, Darryl P. ;
Cosman, Tammy ;
Alhussein, Muhammad M. ;
Tyagi, Nidhi Kumar ;
Karampatos, Sarah ;
Barron, Carly C. ;
Wright, Douglas ;
Tandon, Vikas ;
Magloire, Patrick ;
Joseph, Philip ;
Conen, David ;
Devereaux, P. J. ;
Ellis, Peter M. ;
Mukherjee, Som D. ;
Dhesy-Thind, Sukhbinder .
JACC: CARDIOONCOLOGY, 2019, 1 (01) :1-10
[36]   Immune Checkpoint Inhibitors-Associated Cardiotoxicity [J].
Li, Chenghui ;
Bhatti, Sajjad A. ;
Ying, Jun .
CANCERS, 2022, 14 (05)
[37]   Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study [J].
Lynce, F. ;
Barac, A. ;
Geng, X. ;
Dang, C. ;
Yu, A. F. ;
Smith, K. L. ;
Gallagher, C. ;
Pohlmann, P. R. ;
Nunes, R. ;
Herbolsheimer, P. ;
Warren, R. ;
Srichai, M. B. ;
Hofmeyer, M. ;
Cunningham, A. ;
Timothee, P. ;
Asch, F. M. ;
Shajahan-Haq, A. ;
Tan, M. T. ;
Isaacs, C. ;
Swain, S. M. .
BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (03) :595-603
[38]  
Mahmood S, 2018, J AM COLL CARDIOL, V71, P699, DOI [10.1016/S0735-1097(18)31240-3, 10.1016/j.jacc.2018.02.037]
[39]   Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer [J].
Mantarro, Stefania ;
Rossi, Marta ;
Bonifazi, Martina ;
D'Amico, Roberto ;
Blandizzi, Corrado ;
La Vecchia, Carlo ;
Negri, Eva ;
Moja, Lorenzo .
INTERNAL AND EMERGENCY MEDICINE, 2016, 11 (01) :123-140
[40]   Global Longitudinal Strain as a Major Predictor of Cardiac Events in Patients with Depressed Left Ventricular Function: A Multicenter Study [J].
Mignot, Aude ;
Donal, Erwan ;
Zaroui, Amira ;
Reant, Patricia ;
Salem, Adrien ;
Hamon, Cecile ;
Monzy, Severine ;
Roudaut, Raymond ;
Habib, Gilbert ;
Lafitte, Stephane .
JOURNAL OF THE AMERICAN SOCIETY OF ECHOCARDIOGRAPHY, 2010, 23 (10) :1019-1024